Edwards Lifesciences Co. (NYSE:EW) Stock Position Raised by Tokio Marine Asset Management Co. Ltd.

Tokio Marine Asset Management Co. Ltd. grew its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 8.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,140 shares of the medical research company’s stock after purchasing an additional 1,480 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Edwards Lifesciences were worth $1,197,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Metis Global Partners LLC increased its holdings in Edwards Lifesciences by 8.8% in the third quarter. Metis Global Partners LLC now owns 41,209 shares of the medical research company’s stock worth $2,719,000 after buying an additional 3,340 shares during the last quarter. KBC Group NV raised its position in shares of Edwards Lifesciences by 13.2% in the third quarter. KBC Group NV now owns 896,162 shares of the medical research company’s stock valued at $59,137,000 after purchasing an additional 104,499 shares during the period. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund grew its stake in Edwards Lifesciences by 422.3% in the 3rd quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund now owns 450,233 shares of the medical research company’s stock valued at $29,711,000 after buying an additional 364,030 shares during the last quarter. Oppenheimer & Co. Inc. grew its position in shares of Edwards Lifesciences by 3.9% in the third quarter. Oppenheimer & Co. Inc. now owns 38,186 shares of the medical research company’s stock valued at $2,520,000 after purchasing an additional 1,441 shares during the last quarter. Finally, Saturna Capital Corp lifted its holdings in shares of Edwards Lifesciences by 7.1% during the third quarter. Saturna Capital Corp now owns 24,534 shares of the medical research company’s stock worth $1,619,000 after buying an additional 1,618 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on EW. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research report on Monday, October 28th. TD Cowen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their price target for the stock from $100.00 to $70.00 in a research report on Thursday, July 25th. Robert W. Baird lowered their price objective on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Baird R W lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 25th. Finally, Bank of America lowered shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $105.00 to $75.00 in a report on Thursday, July 25th. Seventeen investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $75.67.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total transaction of $333,850.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,133,916.72. This represents a 9.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the sale, the vice president now directly owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This trade represents a 4.09 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 41,250 shares of company stock worth $2,744,438. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Trading Up 2.4 %

NYSE EW opened at $67.76 on Friday. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The business has a 50 day simple moving average of $67.42 and a 200 day simple moving average of $76.37. The stock has a market capitalization of $39.96 billion, a P/E ratio of 9.78, a P/E/G ratio of 3.74 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same period in the prior year, the business earned $0.59 EPS. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. Research analysts expect that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.